抽象的

The contribution of interleukin-6 signaling to the development of T helper immune response in Chronic Obstructive Pulmonary Disease

 Karolina Sidletskaya

 (COPD). It has been shown that IL-6 acts on T-helper cells (CD4+) and, therefore, impacts the formation of the T helper (Th) immune response, which determines the progression of the pathology. However, the molecular basis of immunoregulatory action of IL-6 in COPD has not been sufficiently studied. The aim of this study is to assess expression level of the membrane receptor for IL-6 (IL-6R/CD126+) on CD4+ cells in patients with COPD of varying severity with different types of Th immune response. Methodology: The study included 98 patients with stable COPD (34 mild, 45 moderate, 19 severe) and 32 healthy volunteers. The type of Th immune response was determined by calculating the ratio of the concentrations of serum cytokines ??? TNF-?, IFN-?, IL-4, -6, -10, -17A (BD, USA). Cytokine levels and the number of blood CD4+CD126+ cells were assessed by flow cytometry (cytometer ???BD FACSCanto II???, USA). Findings: Th1 and Th17 immune response were found in stable COPD. The number of CD4+CD126+ cells was increased by 111% (p<0.001) in patients with severe COPD with Th1 immune response compared to healthy persons. The levels of CD4+CD126+ cells was elevated by 47% (p<0.05), 117% (p<0.01) and 286% (p <0.01) in patients with mild-to-severe COPD with Th17 pathway, respectively compared to the control group. Conclusions: Systemic inflammation in stable COPD develops predominantly according to Th1 or Th17 immune response. Increasing the expression level of IL-6R on blood CD4+ cells is a possible mechanism for enhancing the Th17 immune response as COPD progresses. Th1 immune response is characterized by the raised expression of IL-6R on blood CD4+ cells only in patients with severe COPD. It may be associated with the repolarization of this phenotype towards Th17 as the disease progresses. Recent Publications 1. Vitkina T I, Denisenko Y K and Sidletskaya K A (2017) Changes in the surface IL-6 receptor expression of distinct immune cells in progression of chronic obstructive pulmonary disease. Medical Immunology 19(2):191???196. 2. Cosmi L, Liotta F and Annunziato F (2016) Th17 regulating lower airway disease. Current Opinion Allergy Clinical Immunology 16(1):1-6. 3. Wolf J, Rose-John S, Garbers C (2014) Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70(1):11???20. 4. Ferrari R, Tanni S E, Caram L M O, Correa C, Correa C R, et al. (2013) Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respiratory Research 14(24). 5. Rincon M and Irvin C G (2012) Role of IL-6 in asthma and other inflammatory pulmonary diseases. International Journal of Biological Sciences 8(9):1281???1290 I thank the event for giving me an opportunity to speak in front of delegates and many other people from pulmonologists all over the world. I thank everyone for giving good reviews and testimonials for my talk. It was really a great experience for me to attend this two day conference and I enjoyed all the talks at the conference venue and gained lot of knowledge. I am also interested in attending more and more conference of conference series in future. I also suggest young students to attend the conferences organized by conference series to gain knowledge from the talks that speaker’s present. I met colleagues with varying levels of experience in the field of pulmonology.